High-throughput screening (HTS) has become an essential part of the drug discovery process. Due to the rising requirements for both data quality and quantity, along with increased screening cost and the demand to shorten the time for lead identification, increasing throughput and cost-effectiveness has become a necessity in the hit identification process. The authors present a multiplexed HTS for 2 nuclear receptors, the farnesoid X-activated receptor and the peroxisome proliferator-activated receptor delta in a viable cell-based reporter gene assay. The 2 nuclear receptors were individually transfected into human hepatoma cells, and the transient transfected cell lines were pooled for the multiplexed screen. Hits identified by the multiplexed screen are similar to those identified by the individual receptor screens. Furthermore, the multiplexed screen provides selectivity information if ligands selective for one and not the other receptor are one of the hit criteria. The data demonstrate that multiplexing nuclear receptors can be a simple, efficient, cost-effective, and reliable alternative to traditional HTS of individual targets without compromising data quality. (Journal of Biomolecular Screening 2003:239-246) 
INTRODUCTION
T HE NUCLEAR RECEPTOR (NR) SUPERFAMILY, which includes nuclear hormone receptors and orphan nuclear receptors, is a family of ligand-dependent transcription factors that regulate cellular development and metabolism through control of gene expression. 1, 2 Transcriptional activity of these receptors can be regulated by ligand-modulated interaction with coactivator or corepressor proteins. 3, 4 All NRs consist of a variable amino-terminal region, a conserved DNA-binding domain (DBD), a linker region, and a conserved ligand-binding domain (LBD). 5 The most conserved domain among NRs is the DBD, which mediates binding to specific DNA sequences comprising a response element (RE) upstream of target genes. The ligand-binding domain at the carboxy terminus mediates ligand binding and plays a key role in liganddependent transcriptional activation. The amino terminus is the least conserved region within NRs and plays a role in ligandindependent transcription. Nuclear receptors can function as monomers or homo-or hetero-dimers binding to specific RE sequences. Farnesoid-X-activated receptor (FXR) and peroxisome proliferator-activated receptor delta (PPARδ) are members of the nuclear receptor superfamily. FXR has recently been identified as a receptor involved in the control of bile acid metabolism. 6 PPARδ was recently identified as a key regulator of reverse cholesterol transport and high-density lipoprotein metabolism. 7 Both NRs have become attractive therapeutic targets for the development of treatments for cardiovascular diseases.
Screening strategies involving the pooling of samples to reduce the number of samples to be tested have been used in clinical testing for syphilis and HIV. 8, 9 Multiplexed assays have also been widely adopted in genetic analysis, most of which are PCR related, in which a single enzyme polymerase is used for detecting multiple targets. 10, 11 The combining of multiple targets and/or chemistries in a single reaction for high-throughput screening (HTS) has received a lot of attention in recent years. Pooling compounds into smaller libraries can lead to significant reduction in screening time and costs and has been adopted in HTS. 12, 13 The majority of multiplexed assays have been made possible by recent advances in technologies that promise fast and cost-effective technologies, such as high-content screen and mass spectroscopy. 14, 15 Many of these technologies are proprietary and rely on expensive technology, making them unavailable to most researchers. There have been only a few published reports of the application of multiplexed targets in HTS. 16, 17 In this report, we describe the development of a homogeneous, multiplexed, cell-based luciferase reporter gene assay that is sensitive, robust, cost-effective, and high throughput for identifying ligands for 2 nuclear receptors, FXR and PPARδ. The assay relies on the transient transfection of the human hepatoma cell line with 2 plasmids. The first one encodes the NR LBD fused to the Gal4 DBD and is constitutively expressed from a cytomegalovirus (CMV) promoter. The second plasmid carries a luciferase reporter gene placed downstream of the Gal4 response element, therefore creating a system in which luciferase expression is regulated by ligand binding to and activation of the NR LBD . This assay can be performed in both 96-and 384-well formats.
MATERIALS AND METHODS

Materials
Cell culture medium RPMI 1640, with or without phenol red, was purchased from Life Technologies (Gaithersburg, MD). Other cell culture reagents, including penicillin-streptomycin, Opti-MEM, Dulbecco's PBS without CaCl 2 and MgCl 2 , Dulbecco's MEM, and LipofectAMINE 2000 reagent, were also obtained from Life Technologies. Fetal bovine serum (FBS) was purchased from HyClone Laboratories (Logan, UT). Fetal bovine lipoprotein-deficient serum (FBLPDS) was obtained from Intracel Corp. (Frederick, MD). The Steady-Glo luciferase assay system was purchased from Promega Corp. (Madison, WI). White tissue culture-treated assay plates and Microlite TCT 96-well plates were ordered from Thermo Labsystems (Franklin, MA), and Falcon 384-well plates were purchased from Becton Dickinson Labware (Franklin Lakes, NJ). Tissue culture flasks (225 cm 2 ) and cell culture dishes (150 × 25 mm) were purchased from Corning, Inc. (Corning, NY). Chemical compounds GW4064 (a nonsteroidal FXR agonist) 18 and GW501516 (a nonsteroidal PPARδ selective agonist) 7 were synthesized by Gateway Chemical Technology, Inc. (St. Louis, MO).
Transactivation assay
Human hepatoma cell line, Huh7, was maintained in growth medium (RPMI 1640, 10% FBS, penicillin-streptomycin 100 units/mL) at 37°C in an atmosphere of 5% CO 2 . Huh7 cells were plated in cell culture dishes at a density of 50,000 cells/cm 2 for transfection on day 1. Separate transfections were performed for each nuclear receptor, FXR and PPARδ, using LipofectAMINE 2000 transfection reagent 5 h after cell plating. The transfections consisted of a fusion protein construct encoding the Gal4 DBD -NR LBD and a luciferase reporter gene plasmid having 5 repeats of Gal4RE upstream of the luciferase gene. 19 On day 2, cells from the same receptor transfections were trypsinized and pooled in assay medium (RPMI 1640 without phenol red, 2% FBLPDS, penicillinstreptomycin 100 units/mL) to 1 cell suspension containing 50,000 cells/mL. For multiplexing, the cell suspension contained a total of 100,000 cells/mL of equal amount of FXR-and PPARδ-transfected cells. Cells were dispensed into assay plates at 100 µL/well for 384-well plates or 200 µL/well for 96-well plates using a Labsystem Multidrop-384 liquid dispenser (Franklin, MA). Assay plates were prepared in advance, whereby test compounds at 0.5 or 1 µL of 2 mM were pipetted into a 384-or 96-well plate using the Sagian Multipette (Fullerton, CA). Controls, including DMSO and known agonists of the 2 nuclear receptors (GW4064 for FXR and GW501516 for PPARδ), were added at the same volume as test compounds to columns 23 and 24 of 384-well plates and column 12 of 96-well plates. The cells were incubated at 37°C with 5% CO 2 for 24 h. On day 3, the medium was aspirated and luciferase activity was determined using the Steady-Glo luciferase assay system. The plates were incubated at room temperature for 30 min before luciferase activity in relative light units (RLUs) was determined using the Molecular Devices ChemiLuminescence Imaging Plate Reader (CLIPR, Sunnyvale, CA) for 30 sec/plate.
Screening strategy and data analysis
The LOPAC compound collection, a commercially available library from Sigma (St. Louis, MO) containing 640 known biologically active compounds, was screened at 10 µM. These compounds were screened in a 96-well format in duplicate against each nuclear receptor separately and also multiplexed. These assays were performed on separate days using the same protocol. Then, a set of fifty 384-well plates containing 17,600 compounds at 10 µM was screened against each receptor separately and multiplexed. These assays were all performed on the same day, using cells from the same pool of transfectants under the same conditions to reduce day-to-day transfection and experimental variabilities. Individual receptor results of these assays were compared to the multiplexed results.
Data were analyzed to determine fold activation above the average background (DMSO control) value on each plate using the following equation: Fold Activation = (RLU sample /RLU background ). Active compounds were identified as having a significant increase (> 3 × SD) above the mean of all compounds tested on that day. Active compounds from the initial screens were selected and tested at 10 µM against FXR and PPARδ in duplicate to confirm the activity and identification of selective agonists for the receptors. All confirmed active compounds were analyzed for structure identity and purity using liquid chromatography and mass spectrometry. EC 50 values were determined by nonlinear regression analysis of the dose-response curves using Prism software (Graphpad Software, San Diego, CA). Statistical analysis of the data was performed using JMP, version 4 (SAS Institute, Cary, NC). Following data analysis, the data were deposited into an Oracle database in which compound structures were stored as ISIS files. The analyzed data were then visualized, and compound clustering was performed using Spotfire DecisionSite 7.0 (Spotfire, Cambridge, MA).
RESULTS
In the initial screen of the 640 compounds from the LOPAC collection, results from duplicate wells in fold activation were averaged for each receptor in the individual receptor screens as well as the multiplexed screen. Active compounds were identified using the criterion that they should show greater activity than the mean plus 3 standard deviations determined from results obtained on each day. Responses from the individual FXR and PPARδ screens were also combined to determine the theoretical "additive" response of the 2 receptors. These results were compared to the multiplexed results ( Fig. 1 ) and demonstrated a highly significant correlation (r = 0.953, P < 0.0001). Table 1 lists the 20 active compounds identified from the multiplexed and individual receptor initial screens. These compounds were selected and tested in duplicate against the individual receptor for confirmation of activity. Six compounds (compounds 5, 6, 8, 10, 15, and 20) that were found active in both the multiplexed and individual receptor screens were active in the confirmation test. There were 4 compounds that were active in the individual receptor initial screens but were inactive in the multiplexed screen. These 4 compounds failed the confirmation test, suggesting they were false positives. Another 8 compounds found active in the multiplexed screen and not the individual receptor screens also failed the confirmation test. All 12 compounds would be considered marginal, with the most efficacious having only 3.5-fold activation above the background. However, there were 2 compounds (compounds 2 and 18) identified active in the multiplexed screen but missed in both individual receptor initial screens. The 2 compounds were confirmed active in the confirmation test with marginal activity (2.1-and 3.8-fold activation). Compound 5 showed a strong selective induction of FXR in both the initial screen and confirmation test, whereas compound 6 was active to both FXR and PPARδ. The 2 compounds were selected for comparison in a dose-response study for both receptors. Compound 5 demonstrated a selective dose-dependent activation of FXR with no activity at PPARδ up to 50 µM ( Fig. 2A ). Compound 6 appeared nonselective and activated both FXR and PPARδ with similar potency and efficacy ( Fig. 2B ). Further studies showed that compound 6 induced weak luciferase activation in a receptor-independent manner, suggesting its effects might be mediated by enhancement of replication and/or transcription of the reporter plasmid.
A set of 17,600 compounds in fifty 384-well plates was screened at 10 µM (n = 1) against both individual receptors as well I  I  I  I  2  I  I  A  A  I  3  A  I  I  I  I  4  I  I  A  I  I  5  A  I  A  A  I  6  A  A  A  A  A  7  I  I  A  I  I  8  I  A  A  A  I  9  I  I  A  I  I  1 0  A  A  A  A  A  1 1  I  A  I  I  I  12  I  I  A  I  I  13  I  I  A  I  I  14  I  I  A  I  I  1 5  A  A  A  A  A  16  I  I  A  I  I  17  A  I  I  I  I  18  I  I  A  I  A  19  I  I  A  I  I  2 as the multiplexed receptors on the same day. Figure 3 shows a scatterplot of all control wells from the 50 plates. Z′ values 20 were determined using the control agonist for each receptor in the individual receptor initial screens and the multiplexed screen. The Z′ values were almost identical for FXR, 0.713 for the individual FXR screen, and 0.706 for the multiplexed screen. Results were shown in frequency distribution, and statistical cutoff was determined to be ±1.96 from the mean to achieve 95% confidence in selectivity. Eleven compounds were identified as potentially selective FXR agonists and 41 as potentially selective PPARδ agonists. The majority of compounds showed no difference in the activity against the 2 receptors. (B) Hierarchical clustering of the 208 compounds using the standard ISIS structure keys and Ward's clustering algorithm reveals that many of the hits are structurally related. The cluster containing the most selective compound is indicated with a horizontal line for FXR in the right panel and for PPARδ in the left panel. (C) The frequency distribution of the difference in fold activation for compounds in the 2 clusters highlighted in B. The left panel is from the cluster containing the PPARδ-selective compound, and the right panel is from the cluster containing the FXR-selective compound. 8.2 ± 2.2, and 5.2 ± 0.9 for the multiplexed screen, FXR screen, and PPARδ screen, respectively. The FXR and PPARδ responses from individual receptor screens of the 17,600 compounds were analyzed separately as well as combined to calculate the theoretical "additive" response as described previously. The additive data were compared to the multiplexed data and the correlation determined (Fig. 4) . These results also demonstrated a highly significant correlation (r = 0.718, P < 0.0001).
A total of 575 compounds were active in the initial FXR, PPARδ, or the multiplexed screens. These compounds were selected for confirmation tests in duplicate at 10 µM against individual FXR and PPARδ receptors in a 96-well format. This resulted in 208 confirmed actives. To identify potentially selective compounds for the 2 receptors, the difference in fold activation (FXR -PPARδ) for each compound from the confirmation results was determined. Calculation of the standard deviation from the mean resulted in a statistical cutoff at ±1.96 to achieve 95% confidence in selectivity (Fig. 5 ). This analysis shows that 11 FXR agonists and 41 PPARδ agonists are potentially selective ligands for the 2 receptors. Of the 52 potentially selective agonists, 10 were found active only in the individual receptor initial screens and 8 were found active only in the multiplexed screen. All 18 of these compounds were marginally active with respect to fold induction at 10 µM, the most efficacious having only 8.6-fold activation. However, it is interesting to note that of the compounds selective for either FXR or PPARδ, there were compounds structurally related that did not show such selectivity (Fig. 5B,C) . This suggests that it may be possible to find other selective compounds by testing additional compounds similar to the nonselective actives. The majority of compounds, 156 of 208, that were active in the confirmation test showed no selectivity (Fig. 6 ). Three-quarters of the 156 compounds demonstrated marginal activity. The most efficacious has only 8.9-and 8.4-fold activation against FXR and PPARδ, respectively. Of these 156 compounds, 123 (79%) were active in the multiplexed screen and 100 (64%) were active against FXR or PPARδ in the individual receptor initial screens.
DISCUSSION
The nuclear receptor family is a large class of ligand-dependent transcription factors involved in the regulation of genes that play critical roles in a wide array of biological processes. Binding of their natural hormones or synthetic ligands to the ligand-binding domain of these receptors results in conformational changes that facilitate interactions of the receptors with cofactors or coregulators. [21] [22] [23] Coactivators and coregulator proteins that possess histone acetyltransferase and/or chromatin remodeling activities act in a combinatorial/sequential manner to activate gene transcription. 24 Given the widespread relevance of these nuclear receptors to almost all aspects of normal human physiology, the role of these receptors in the etiology of many human diseases, and their importance as therapeutic targets for pharmaceuticals, it is obvious that a detailed understanding of these systems has major implications, not only for human biology but also for the understanding and development of new drug treatments. The reporter gene assay system has been a particularly valuable approach for the successful identification of numerous nuclear receptor ligands, both natural and synthetic, in HTS and secondary assays.
Screening multiple targets at one time in the same well is an area of HTS that has yet to reach its full potential. One important advantage of multiplexed assays is the ability to obtain additional information from the same screen. Because more than 1 target is screened at the same time, the assay provides information on the selectivity of the compound, whether it binds to one and not another target. The second target can be used as an internal standard. In the case of cell-based antagonist screens, the combination of more than one type of assay, such as a reporter gene assay and a cell proliferation assay, allows researchers to distinguish between hits that selectively inhibit the targeted response element and hits that merely are cytotoxic or inhibit cell proliferation. Furthermore, for 2 similar targets, such as the nuclear receptors FXR and PPARδ described in this report, whether the initial hits activate both receptors or are selective to one and not the other receptor can be easily determined during the confirmation tests. The benefit is that multiplexed screening provides more information than a simple yes or no answer to the question of whether a compound is active against the targets of interest.
Our results demonstrate that multiplexing 2 nuclear receptors is equally capable of identifying agonists as compared to screening the receptors separately in a cell-based reporter gene assay. The fact that the multiplexed screen and individual receptor screens re- sulted in having similar Z′ values suggests that multiplexing does not compromise data quality. The multiplexed screen identified both selective and nonselective ligands of the 2 nuclear receptors comparable to that obtained by the individual receptor screens. Of the 11 potentially selective FXR agonists and 41 potentially selective PPARδ agonists, all but 10 were identified as hits in the multiplexed screen. The multiplexed screen identified an additional 8 compounds that were missed by the initial screening of the receptors separately. The 18 missed compounds do not belong to a particular structural class and are randomly distributed among different structural clusters, suggesting that the misses are random and mainly resulted from the weak activity of these compounds at 10 µM. Confirmation tests indicate these 18 compounds are marginally active. These results suggest that there is no significant difference between the multiplexed and individual nuclear receptor screens in identifying selective and potent agonists. Of the 156 nonselective agonists identified, 123 were active in the multiplexed screen, but only 100 were active in the individual receptor screens. This indicates that multiplexing increased the probability of identifying these marginally active, nonselective agonists. The effect could be due to the number of cells in the multiplexed screen, 10,000 cells/well as compared to 5,000 cells/well in the individual receptor screens. As the DMSO control (background) has basically no effect on luciferase activity under our assay conditions, in which there is no significant difference between 5,000 and 10,000 cells (see Fig. 3 ), nonselective receptor agonists may induce higher luciferase activity in the presence of more cells in the well. This may be why relatively more false positives were also identified from the multiplexed screens of the LOPAC collection and the 17,600 compound set.
An advantage of identifying additional actives, even if they prove to be weak or nonselective, is that they may be related to compounds that do show selectivity. This is demonstrated by clustering of the active molecules using commercially available software to describe the molecular structures of the compounds and to cluster these structures using Ward's algorithm. Ward's clustering was chosen as it had been described as the most robust method for clustering compounds to reflect their biological activity, but it is possible that other molecular descriptors and clustering methods may also prove appropriate. 25, 26 This implies that although the majority of the active compounds may fail to show selectivity, it is possible that further rounds of sequential screening focused around sets of compounds similar to such hits could yield active and selective compounds.
Here we present an ideal situation for multiplexing nuclear receptor targets for HTS because both FXR and PPARδ work in the same cell line and assay conditions. The use of different cell lines for transfections and pooling should be possible if media requirements can be compromised for different receptors. It is equally important that transfected FXR and PPARδ cells have a similar level of basal luciferase activity so that sensitivity of 1 receptor will not be interfered with by the other with a higher background. The level of receptor expression has not been normalized between the 2 transiently transfected cell lines, but the basal level of luciferase expression under our assay conditions is very low, approaching plate background, for both FXR and PPARδ. In the multiplexed screen, hits identified can be easily deconvoluted and selectivity determined in the confirmation test. Alternatively, one could use a dual-reporter approach 27 by transfecting 1 receptor with a firefly luciferase reporter and the other receptor using a Renilla luciferase reporter so that luciferase signals induced by the 2 receptors would not interfere with one another. However, when considering an initial hit rate of only a few percent, the dual-reporter approach would be costly and time-consuming because the procedure involves reading 2 luciferase substrates, one after the other.
The savings in screening time and cost and the reduction of compound consumption for multiplexing these nuclear receptors are significant. If a full HTS were initiated for both FXR and PPARδ, the primary screen would be essentially reduced to half, excluding cell culture, with respect to both time and cost. The resources needed would also be reduced, and hit identification time could be shortened because a statistical measure of selectivity could be applied immediately if a selective ligand were one of the hit criteria. This approach could reduce the number of follow-up compounds, which would be up to 75% of the hits identified in this report.
